Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420787 | 0.84 | BCHE (0.44) | MCL1BCHEACHEF12PDE4A | |
| SCHEMBL6420033 | 0.80 | MCL1 (0.57) | MCL1BCHEACHEPDE4APDE4B | |
| SCHEMBL6419389 | 0.80 | PDE4A (0.59) | MCL1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6434898 | 0.79 | MCL1 (0.56) | MCL1BCHEACHEPDE4APDE4B | |
| SCHEMBL6420070 | 0.79 | PDE4A (0.56) | MCL1BCHEACHEPDE4APDE4B | |
| SCHEMBL6420149 | 0.79 | MCL1 (0.51) | MCL1BCHEACHEPDE4APDE4B | |
| SCHEMBL6421831 | 0.77 | PDE4A (0.46) | MCL1BCHEACHEPDE4APDE4B | |
| SCHEMBL6425432 | 0.74 | MEN1 (0.66) | MCL1BCHEACHEF12PDE4A | |
| SCHEMBL6420547 | 0.72 | MCL1 (0.73) | MCL1BCHEACHEPDE4APDE4B | |
| SCHEMBL6423552 | 0.71 | ABCB1 (0.52) | MCL1BCHEACHEF12PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | MCL1 3567/4885BCHE 421/4885ACHE 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.